['al amyloidosis']
['neod001', 'placebo']

        Inclusion Criteria:

          1. Age ≥18 years

          2. Confirmed diagnosis of systemic AL amyloidosis

          3. ≥1 prior systemic plasma cell dyscrasia therapy with at least a partial hematologic
             response

          4. Cardiac involvement

          5. NT-proBNP ≥650

        Exclusion Criteria:

          1. Non-AL amyloidosis

          2. Meets the International Myeloma Working Group (IMWG) definition of Multiple Myeloma

          3. NT-proBNP >5000

          4. Received Plasma cell directed chemotherapy within 6 months

          5. Received autologous stem cell transplant (ASCT) within 12 months
      